Feng Yuan, Lin Zhaoguo, Hu Wenzhu, Wang Xingyi, Zhang Zihan, Lan Xiaoli, Zhang Xiao
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, Hubei Province, China.
Mol Pharm. 2025 Apr 7;22(4):2122-2130. doi: 10.1021/acs.molpharmaceut.4c01314. Epub 2025 Mar 25.
Immunotherapy-induced tumor apoptosis is one of the crucial pathways in tumor cell death. This study aimed to explore the potential of PET imaging for noninvasively visualizing pivotal processes in immunotherapy, specifically immune activation and tumor apoptosis, by targeting granzyme-B and caspase-3. Bioinformatic analyses validated granzyme-B and caspase-3 expression in cancer tissues and their associations with immune infiltration and patient prognosis using the GEPIA and TIMER databases. Two radiolabeled probes, [Ga]Ga-GZP and [Ga]Ga-AC3, were used to specifically target granzyme-B and caspase-3 for PET imaging, respectively. CT26 xenograft tumor models were assigned to PD-1 inhibitor or PBS control groups to receive treatment every 3 days, with imaging conducted at baseline and after each treatment. Imaging results showed significantly increased tumor uptake of both [Ga]Ga-GZP and [Ga]Ga-AC3 in the ICB-treated group compared to controls, indicating early molecular changes in immune activation and tumor apoptosis. Immunofluorescence analysis further supported these findings, revealing upregulated granzyme-B and caspase-3 expression in treated tumor tissues. Immunohistochemistry also confirmed increased T-cell infiltration and elevated levels of effector molecules, such as IFN-γ and TNF-α, in the ICB group. This study demonstrates that granzyme-B and caspase-3 PET/CT can noninvasively visualize early molecular changes in immunotherapy-induced CD8 T cell activation and tumor apoptosis. These noninvasive diagnostic techniques hold significant promise for future clinical applications, particularly for a more accurate evaluation of immunotherapy efficacy.
免疫疗法诱导的肿瘤细胞凋亡是肿瘤细胞死亡的关键途径之一。本研究旨在探索PET成像通过靶向颗粒酶B和半胱天冬酶-3对免疫疗法中的关键过程(特别是免疫激活和肿瘤细胞凋亡)进行无创可视化的潜力。生物信息学分析使用GEPIA和TIMER数据库验证了癌症组织中颗粒酶B和半胱天冬酶-3的表达及其与免疫浸润和患者预后的关联。两种放射性标记探针,[Ga]Ga-GZP和[Ga]Ga-AC3,分别用于特异性靶向颗粒酶B和半胱天冬酶-3进行PET成像。将CT26异种移植肿瘤模型分为PD-1抑制剂组或PBS对照组,每3天接受一次治疗,在基线和每次治疗后进行成像。成像结果显示,与对照组相比,ICB治疗组中[Ga]Ga-GZP和[Ga]Ga-AC3的肿瘤摄取均显著增加,表明免疫激活和肿瘤细胞凋亡的早期分子变化。免疫荧光分析进一步支持了这些发现,揭示了治疗后肿瘤组织中颗粒酶B和半胱天冬酶-3的表达上调。免疫组织化学也证实了ICB组中T细胞浸润增加以及效应分子如IFN-γ和TNF-α水平升高。本研究表明,颗粒酶B和半胱天冬酶-3 PET/CT可以无创地可视化免疫疗法诱导的CD8 T细胞激活和肿瘤细胞凋亡的早期分子变化。这些无创诊断技术在未来临床应用中具有巨大潜力,特别是在更准确评估免疫疗法疗效方面。